Compare BIO-TECHNE Corp (TECH) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs State Street Technology Select Sector SPDR ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while State Street Technology Select Sector SPDR ETF trades at $187.13. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while State Street Technology Select Sector SPDR ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, State Street Technology Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals.
| TECH | XLK | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Sector/Thematic |
52-Week High | $72.29 | $198.21 |
52-Week Low | $43.31 | $127.49 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
XLK, the Technology Select Sector SPDR ETF, trades at $187.97, up 1.42% with a bullish technical signal driven by moving averages. The ETF benefits from strong sector inflows and AI-driven tech earnings, though RSI levels hint at overbought conditions. Recent news highlights record $25 billion inflows into sector ETFs in July 2026, with tech leading gains.
Outlook remains positive amid robust earnings growth and institutional optimism, but risks include overconcentration in mega-caps and valuation concerns. The ETF's performance hinges on continued tech sector strength and Federal Reserve policy easing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
